KRAS and neoplasm: Regarding potential downstream targets, a publication by Chow et al. 42 reported that in PDAC cells, oncogenic KRAS/ERK helps in TGFβ-induced downregulation of PTEN at the mRNA level, which in turn could help promote tumor growth.